Last quarter (Q3 2023), Candel Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Candel Therapeutics's net income was $-8.44M. See Candel Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 7.00K	$ 100.00K	$ 100.00K	$ 125.00K	$ 125.00K
Cost of Revenue	-	-	-	-	-
Gross Profit	$ 7.00K	$ 100.00K	$ 100.00K	-	-
Operating Expense	$ 19.94M	$ 34.85M	$ -25.85M	$ 13.31M	$ 8.59M
Operating Income	$ -36.20M	$ -34.72M	$ -25.75M	$ -13.19M	$ -8.47M
Net Non Operating Interest Income Expense	$ -132.00K	-	$ -53.00K	$ 111.00K	$ 1.07M
Other Income Expense	$ -4.28M	$ -15.93M	$ 10.35M	$ -4.61M	$ -844.00K
Pretax Income	$ -31.95M	$ -18.82M	$ -36.15M	$ -17.68M	$ -8.24M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -31.95M	$ -18.82M	$ -36.15M	$ -17.68M	$ -8.24M
Basic EPS	$ -1.13	$ -0.65	$ -1.91	$ -0.95	$ -0.44
Diluted EPS	$ -1.10	$ -0.65	$ -1.91	$ -0.95	$ -0.44
Basic Average Shares	$ 115.58M	$ 28.82M	$ 18.87M	$ 18.68M	$ 18.68M
Diluted Average Shares	$ 115.58M	$ 28.82M	$ 18.87M	$ 18.68M	$ 18.68M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	$ 256.00K	$ 204.00K
Total Expenses	$ 19.94M	$ 34.85M	$ -25.85M	$ 13.31M	$ 8.59M
Net Income From Continuing And Discontinued Operation	$ -31.95M	$ -18.79M	$ -36.15M	$ -17.68M	$ -8.24M
Normalized Income	$ -7.60M	$ -14.87M	-	$ -13.07M	$ -8.24M
Interest Expense	-	-	-	-	-
EBIT	$ -30.97M	$ -18.82M	$ -36.10M	$ -13.19M	$ -8.47M
EBITDA	$ -22.20M	$ -18.04M	$ -36.30M	$ -13.10M	$ -8.42M

Currency in USD

Candel Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing